Therapeutic plasma exchange may allow patients with advanced melanoma to overcome immune checkpoint inhibitor resistance, data suggest.

First investigational drug candidate using the HUTCHMED ATTC technology platform to create potent targeted therapy payloads while mitigating ...

Adia Nutrition Inc. (OTCQB: ADIA) is excited to announce the appointment of Evan Thomas, MD, PhD, as an Independent Medical Director for its medical division, Adia Med. A renowned radiation oncologist ...

As Mike Petegorsky prepared to welcome his baby daughter, he worked to minimize his family’s exposure to microplastics and other environmental toxins. The telehealth executive got rid of plastic ...

Endo announces the U.S. launch of a generic version of RAVICTI® (glycerol phenylbutyrate), marking a significant milestone as ...

Cohen's Point72 purchased over 8 million shares of C4 Therapeutics within weeks of the company announcing phase 1 trial data ...

Plenty of international performers visit our shores, play their concerts, sell their wares then move on to the next territory ...

(Nasdaq: ALEC), a clinical-stage biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced results from the Phase 3 ...

Viking Therapeutics, Inc. ( NASDAQ: VKTX) Q3 2025 Earnings Call October 22, 2025 4:30 PM EDT Welcome to the Viking Therapeutics Third Quarter 2025 Financial Results Conference Call. [Operator ...

Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), today announced positive results from its Phase 2 study of oral, once-daily VTX3232 in patients with Obesity and Cardiovascular Risk ...